<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953093</url>
  </required_header>
  <id_info>
    <org_study_id>2016-6933</org_study_id>
    <nct_id>NCT02953093</nct_id>
  </id_info>
  <brief_title>Study of Acarbose in Longevity</brief_title>
  <acronym>SAIL</acronym>
  <official_title>Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying the effects of acarbose on muscle and adipose gene
      transcription in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acarbose, an FDA approved drug for the treatment of type 2 diabetes, has known effects on
      glucose metabolism. Evidence from mice indicates that acarbose may prolong lifespan. In
      humans, acarbose improves inflammatory markers and reduces cardiovascular events.
      Consequently, acarbose is of interest in clinical translational aging research since it may
      influence fundamental processes that contribute to age-related diseases. The study described
      herein is an exploratory study to examine the effect of acarbose treatment on the biology of
      aging in humans. Specifically, the investigators plan to study whether treatment with a 10
      week course of acarbose will alter the gene expression profile in adipose tissue and muscle
      in older adults in pathways that are known to be affected by human aging, in a
      placebo-controlled crossover study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue gene expression after placebo vs after acarbose.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Difference in gene expression in muscle and abdominal adipose tissue (with adjusted p-value less than 0.05, and a fold change greater than 2) using RNA-seq analysis after 10 weeks of acarbose compared to 10 weeks of placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum microRNA</measure>
    <time_frame>10 weeks</time_frame>
    <description>Difference in microRNA expression level (with adjusted p &lt;0.05) after 10 weeks of acarbose compared to 10 weeks of placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome</measure>
    <time_frame>10 weeks</time_frame>
    <description>Difference in 16s rDNA gene sequence expression level (with adjusted p &lt;0.05) after 10 weeks of acarbose compared to 10 weeks of placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Acarbose first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Acarbose first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
    <other_name>Precose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Acarbose first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  age &gt;60 years

          -  impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)

        Exclusion Criteria:

          -  cancer

          -  heart failure

          -  COPD

          -  inflammatory conditions

          -  eGFR&lt;45

          -  active liver disease

          -  poorly controlled hypertension

          -  epilepsy

          -  recent cardiovascular disease event (last 6 months)

          -  inflammatory bowel disease

          -  history of bariatric or other gastric surgery

          -  cigarette smoking

          -  serious substance abuse.

          -  Treatment with drugs known to influence glucose metabolism

          -  Hypersensitivity to acarbose or any component of the formulation.

          -  Treatment with anti-coagulant medications or anti-platelet drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika F Brutsaert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine/ Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erika F Brutsaert, MD</last_name>
    <phone>7188397961</phone>
    <email>erika.brutsaert@einstein.yu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nir Barzilai, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika F Brutsaert, MD, MPH</last_name>
      <phone>866-633-8255</phone>
    </contact>
    <investigator>
      <last_name>Erika F Brutsaert, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Erika Brutsaert</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>acarbose</keyword>
  <keyword>aging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data to researchers who are not part of the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

